Sign in

Stephen P. MacMillan

Chairman, President, and CEO at HOLOGIC
Board
Since December 6, 2013
Age
61 years
Education
Holds a Bachelor of Arts degree in economics from Davidson College and is a graduate of Harvard Business School’s Advanced Management Program.
Tenure
Joined HOLX on December 6, 2013 as President, CEO, and a director, and was elected Chairman in June 2015.

Also at HOLOGIC

BS
Brandon Schnittker
Division President, GYN Surgical Solutions
DDW
Diana De Walt
Senior Vice President, Human Resources
EDM
Essex D. Mitchell
Chief Operating Officer (COO)

About

Stephen P. MacMillan, age 61 as of January 2025 , has built a distinguished career underpinned by a strong educational foundation, holding a Bachelor of Arts in economics from Davidson College and completing the Advanced Management Program at Harvard Business School.

He began his leadership journey at HOLX when he joined as President, CEO, and a director on December 6, 2013 and later expanded his role by being elected Chairman in June 2015. His tenure at the company has been marked by strategic decision-making and transformational leadership.

Before joining HOLX, he garnered extensive experience in the healthcare and consumer industries with key roles at Stryker Corporation, Pharmacia Corporation, Johnson & Johnson, and sBioMed, LLC. His broad expertise and commitment to operational excellence continue to drive HOLX’s growth and innovation, making him a respected leader in the industry.

$HOLX Performance Under Stephen P. MacMillan

Past Roles

OrganizationRoleDate RangeDetails
sBioMed, LLC Chief Executive Officer October 2012 - December 2013 NA
Stryker Corporation Chief Executive Officer 2005 - 2012 NA
Stryker Corporation Chairman 2010 - 2012 NA
Stryker Corporation Chief Operating Officer 2003 - 2005 NA
Pharmacia Corporation Senior Executive (overseeing five global businesses) Prior to 2003 NA
Johnson & Johnson Senior Roles including President of its consumer pharmaceuticals joint venture with Merck N/A 11 years in the US and Europe
Procter & Gamble Various Early Career Roles Beginning in 1985 NA

External Roles

OrganizationRoleDate RangeDetails
Illumina, Inc. Board of Directors N/A Current position

Fixed Compensation

Data from  FY 2024
Component NameAmountPayment ScheduleAdditional Details
Base Salary$1,212,628 AnnualFixed annual base salary for fiscal 2024
All Other Compensation$537,275 AnnualIncludes various benefits and perquisites; detailed breakdown not provided

Performance Compensation

Data from  FY 2024

Non-Equity Incentive Plan (Annual Cash Incentive Awards)

MetricThresholdTargetMaximumWeight (%)
Annual Cash Incentive$909,471 $1,818,942 $3,637,884 N/A
  • Evaluation Period: Fiscal 2024.
  • Actual Results: Overall payout reached 109% of the target; Adjusted Revenue achieved 91% of target and Adjusted EPS 134% of target.

Performance Stock Units (PSUs)

PSU TypeThreshold (units)Target (units)Maximum (units)Grant Date Fair Value (USD)
FCF PSUs10,208 20,416 40,832 $2,937,454
ROIC PSUs10,208 20,416 40,832 $1,468,727
TSR PSUs10,208 20,416 40,832 $1,797,833
  • Performance Metrics:
    • FCF PSUs: Based on cumulative adjusted Free Cash Flow; no vesting if performance is below $2,100M.
    • ROIC PSUs: Tied to three-year average adjusted ROIC.
    • TSR PSUs: Determined by relative Total Shareholder Return with thresholds at the 25th, 50th, and 95th percentiles.
  • Vesting Schedule: Cliff vesting at the end of three years (November 2026).
  • Grant Date: November 14, 2023.
  • Evaluation Period: Three years (Fiscal 2024–2026).

Long-Term Incentive Award Grants

ComponentPerformance MetricThresholdTargetMaximum
FCF PSUsCumulative Adjusted FCF$2,100M $2,900M $3,500M
ROIC PSUsAdjusted ROIC10% 13% 16%
TSR PSUsRelative TSR (Peer Percentile)Below 25th percentile 50th percentile 95th percentile
  • Vesting: RSUs vest in three equal annual installments; stock options vest in four equal annual installments.
  • Grant Details:
    • Grant Date: November 14, 2023.
    • Grant Date Fair Values: $2,937,454 for stock awards and $2,937,477 for option awards.
    • Grant Date Stock Price: $71.94 per share.
  • Evaluation Period: Three years for the PSUs.